ClinicalTrials.gg
Active, not recruitingNCT06525220Updated Nov 2, 2026

A Phase 3 Study to Evaluate Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Head and Neck Cancer (LiGeR - HN1)

A Phase 3 interventional study of Petosemtamab and Pembrolizumab in Head and Neck Squamous Cell Carcinoma, sponsored by Genmab. Active, not recruiting at 202 sites in 28 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-02.

Sponsored by Genmab · Phase 3, Interventional, and Treatment

Updated Nov 2, 2026Now Active, not recruitingSponsor changed+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
699
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,099 studies in Squamous Cell Carcinoma of Head and Neck with a site in United States — 217 open to participants now, 347 under way, 28 of them phase 3. Squamous Cell Carcinoma of Head and Neck · United States.

Enrollment
21st of 993
699 · median 41
Started
2024
with 64 others
Phase 3
71 of 1,099
12 open now
Primary completion
2028-01
later than 206 of 346 live
Registered
970th of 1,099
by date

Among the 1,099 studies in Squamous Cell Carcinoma of Head and Neck with a site in United States, this one is the 21st largest by enrollment of the 993 interventional ones that give a count, is one of 65 that started in 2024, is one of 71 in phase 3, reaches primary completion later than 206 of the 346 other live ones, and was the 970th registered.

Squamous Cell Carcinoma of Head and Neck

2,019 studies on the registry are indexed under Squamous Cell Carcinoma of Head and Neck; 573 are open to participants now.

Browse Squamous Cell Carcinoma of Head and Neck studies →

Open to participants now

217 of the 1,099 studies in Squamous Cell Carcinoma of Head and Neck with a site in United States are open now. Recruiting first, the newest first:

212 more — sign in →

All 217 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 435 Squamous Cell Carcinoma of Head and Neck studies recruiting now, 311 (71%) set no upper age limit and 87 (20%) stop at 75 or younger; 5 take children under 18; 13 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,099 studies in Squamous Cell Carcinoma of Head and Neck with a site in United States, or all of them as a file.
02

Study summary

This is a Phase 3 randomized, open-label study to evaluate the efficacy and safety of petosemtamab plus pembrolizumab vs pembrolizumab in first-line treatment of recurrent or metastatic PD-L1+ head and neck squamous cell carcinoma.

Read the detailed description

This is a Phase 3 randomized, open-label study to evaluate the efficacy and safety of petosemtamab plus pembrolizumab vs pembrolizumab in first-line treatment of recurrent or metastatic PD-L1+ HNSCC. HNSCC patients should not have had previous systemic therapy administered in the incurable recurrent or metastatic setting, although previous systemic therapy as part of multimodal treatment for locally advanced disease is allowed if PD was ≥6 months after the last platinum-containing therapy dose. Previous treatments with anti PD-(L)1 or anti-EGFR therapies are not allowed. In the case of cetuximab, patients who have received cetuximab with radiotherapy as a local treatment and PD was >1 year after the last dose of cetuximab are eligible.

03

Conditions studied

  • Head and Neck Squamous Cell Carcinoma

Keywords

  • HNSCC
  • PD-L1+
  • Head and Neck cancer
  • Petosemtamab
  • Pembrolizumab
  • Liger
  • Oral Cavity
  • Oropharynx
  • Larynx
  • Hypopharynx
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Signed ICF before initiation of any study procedures
  2. Age ≥ 18 years at signing of ICF
  3. confirmed HNSCC with evidence of or locally recurrent disease not amenable to local therapy with curative intent.
  4. The eligible HNSCC primary tumor locations are oropharynx, oral cavity, hypopharynx, and larynx.
  5. HNSCC patients eligible to receive pembrolizumab as 1L monotherapy with tumors expressing , CPS ≥1.
  6. HNSCC patients should not have had previous systemic therapy administered in the incurable recurrent or metastatic setting
  7. A new tumor , unless the patient has an available archival tumor sample with sufficient material
  8. per Investigator assessment as defined by v1.1 by radiologic methods
  9. Performance Status (PS) of 0-1
  10. ≥ 12 weeks, as per investigator assessment.
  11. (LVEF) ≥50% by echocardiogram (ECHO) or multigated acquisition (MUGA) scan
  12. Adequate organ function as defined per protocol.
  13. -positive patients are eligible only if the cluster of differentiation 4 (CD4+) count is ≥ 300/µl, viral load is undetectable, and the patient is currently receiving highly active antiretroviral therapy

Exclusion criteria

Exclusion Criteria:

  1. Central nervous system that are untreated or already treated but symptomatic, or require radiation, surgery, or continued therapy to control symptoms within 21 days prior to randomization
  2. Known
  3. Any systemic anticancer therapy or drug within 4 weeks or 5 half-lives, whichever is shorter, before randomization
  4. Requirement for medication
  5. Major surgery or radiotherapy within 3 weeks of randomization
  6. toxicities related to prior anticancer therapies that have not returned to ≤ Grade 1 or baseline except for Grade ≤2- myalgia, neuropathy, alopecia, and any prior therapy related endocrinopathies
  7. History of reaction to any of the of petosemtamab or pembrolizumab.
  8. Unstable angina; history of congestive heart failure of Class II-IV (NYHA) criteria, or serious cardiac arrhythmia requiring treatment; or history of myocardial infarction within 6 months prior to randomization
  9. History of prior within the last 5 years, with the exception of excised local cancer
  10. Current dyspnea at rest of any origin, or other diseases requiring continuous oxygen therapy
  11. Current serious illness or medical conditions including, but not limited to, uncontrolled active infection, clinically significant pulmonary, metabolic or psychiatric disorders
  12. Patients with known infectious diseases as per protocol.
  13. Pregnant or breastfeeding patients.
  14. The patient has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy of prednisone >10 mg/day or equivalent, or any other form of immunosuppressive therapy
  15. The patient has an active disease that has required systemic immune suppressive treatment in the past 2 years; replacement therapy is not considered immune suppressive treatment
  16. The patient has had an allogeneic tissue/solid organ transplant.
  17. Patient has a primary tumor site of nasopharynx, or sinonasal carcinoma (any histology)

Other protocol defined inclusion/exclusion criteria may apply.

Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
699 participants (actual)

Study arms

  • Experimental
    Petosemtamab + Pembrolizumab

    Combination Therapy

    Drug: Petosemtamab · Drug: Pembrolizumab

  • Active comparator
    Pembrolizumab

    Monotherapy

    Drug: Pembrolizumab

Interventions

06

What researchers measure

Primary outcomes

  1. Overall Survival (OS)

    Time frame: Up to approximately 3 years

  2. Objective Response Rate (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 as assessed by blinded independent central review (BICR)

    Time frame: Up to approximately 2 years

Secondary outcomes

  1. Progression Free Survival (PFS) per RECIST v1.1 as assessed by BICR

    Time frame: Up to approximately 2 years

  2. Duration of Response (DOR) per RECIST v1.1 as assessed by BICR

    Time frame: Up to approximately 2 years

  3. Clinical benefit rate per RECIST v1.1 as assessed by BICR

    Time frame: Up to approximately 2 years

  4. Time to response (TTR) per RECIST v1.1 as assessed by BICR

    Time frame: Time Frame: Up to approximately 2 years

  5. Objective response rate per RECIST v1.1 as assessed by investigator review

    Time frame: Up to approximately 2 years

  6. Progression-free survival per RECIST v1.1 as assessed by investigator review

    Time frame: Up to approximately 2 years

  7. Duration of response per RECIST v1.1 as assessed by investigator review

    Time frame: Up to approximately 2 years

  8. Time to response (TTR) per RECIST v1.1 as assessed by Investigator

    Time frame: Time Frame: Up to approximately 2 years

  9. Clinical benefit rate per RECIST v1.1 as assessed by investigator review

    Time frame: Up to approximately 2 years

  10. Number of participants who experienced at least one treatment emergent adverse event (TEAE)

    Time frame: Up to 30 days post last dose

  11. Number of participants who experienced at least one serious TEAE

    Time frame: Up to 30 days post last dose

  12. Number of participants who discontinued study treatment due to TEAEs

    Time frame: Up to 30 days post last dose

  13. Number of participants who had dose modification due to TEAEs

    Time frame: Up to 30 days post last dose

  14. To evaluate patient reported outcomes for health-related quality of life

    Time frame: Up to approximately 2 years

  15. Pharmacokinetic parameters

    Time frame: Up to first 6 cycles

  16. Incidence of anti-drug antibodies (ADAs)

    Time frame: Up to 30 days post last dose

07

Study locations

202 sites
  • Site 164
    Mobile, Alabama 36607, United States
  • Site 36
    La Jolla, California 92037, United States
  • Site 27
    Los Angeles, California 90033, United States
  • Site 16
    Palo Alto, California 94304, United States
  • Site 19
    Newark, Delaware 19713, United States
  • Site 108
    Washington D.C., District of Columbia 20010, United States
  • Site 14
    Fort Myers, Florida 33901, United States
  • Site 8
    Orlando, Florida 32827, United States
  • Site 21
    St. Petersburg, Florida 33705, United States
  • Site 20
    West Palm Beach, Florida 33401, United States
  • Site 171
    Atlanta, Georgia 30322, United States
  • Site 197
    Chicago, Illinois 60611, United States
  • Site 50
    Chicago, Illinois 60637, United States
  • Site 2
    Louisville, Kentucky 40202, United States
  • Site 162
    Baton Rouge, Louisiana 70809, United States
  • Site 155
    Minneapolis, Minnesota 55417, United States
  • Site 168
    St Louis, Missouri 63108, United States
  • Site 94
    Hackensack, New Jersey 07601, United States
  • Site 6
    Albuquerque, New Mexico 87131, United States
  • Site 113
    Durham, North Carolina 27710, United States
  • Site 118
    Winston-Salem, North Carolina 27157, United States
  • Site 191
    Cleveland, Ohio 44195, United States
  • Site 43
    Philadelphia, Pennsylvania 19104, United States
  • Site 153
    Philadelphia, Pennsylvania 19107, United States
  • Site 154
    Philadelphia, Pennsylvania 19114, United States
  • Site 89
    Chattanooga, Tennessee 37404, United States
  • Site 115
    Memphis, Tennessee 38103, United States
  • Site 88
    Nashville, Tennessee 37203, United States
  • Site 22
    Austin, Texas 78745, United States
  • Site 1
    Houston, Texas 77030, United States
  • Site 18
    Plano, Texas 75075, United States
  • Site 17
    Sugar Land, Texas 77479, United States
  • Site 15
    Tyler, Texas 75702, United States
  • Site 10
    Salt Lake City, Utah 84112, United States
  • Site 12
    Blacksburg, Virginia 24060, United States
  • Site 23
    Norfolk, Virginia 23502, United States
  • Site 170
    CABA, C1113AAE, Argentina
  • Site 96
    CABA, C1118AAT, Argentina
  • Site 31
    Córdoba, X5008HHW, Argentina
  • Site 30
    La Rioja, 5300, Argentina
  • Site 76
    Rosario, S2000KZE, Argentina
  • Site 46
    Viedma, R8500ACE, Argentina
  • Site 11
    Blacktown, New South Wales 2148, Australia
  • Site 24
    St Leonards, New South Wales 2065, Australia
  • Site 166
    Greenslopes, Queensland 4120, Australia
  • Site 151
    Melbourne, Victoria 3004, Australia
  • Site 53
    Brussels, 1200, Belgium
  • Site 98
    Edegem, 2650, Belgium
  • Site 99
    Ghent, 9000, Belgium
  • Site 71
    Leuven, 3000, Belgium
  • Site 109
    Liège, 4000, Belgium
  • Site 63
    Namur, 5000, Belgium
  • Site 141
    Belo Horizonte, 30.360-680, Brazil
  • Site 144
    Natal, 59020-340, Brazil
  • Site 140
    Porto Alegre, 90610-000, Brazil
  • Site 142
    Porto Alegre, 91350-200, Brazil
  • Site 137
    Recife, 50040-000, Brazil
  • Site 149
    Rio de Janeiro, 22.250-905, Brazil
  • Site 138
    Rio de Janeiro, 22281-100, Brazil
  • Site 134
    São Paulo, 01509-900, Brazil
  • Site 136
    São Paulo, 04538-132, Brazil
  • Site 165
    St. John's, A1B3V6, Canada
  • Site 44
    Toronto, M5G 2M9, Canada
  • Site 111
    Winnipeg, R3E0V9, Canada
  • Site 38
    Antofagasta, 1263521, Chile
  • Site 26
    Providencia, 7500859, Chile
  • Site 29
    Recoleta, 8420000, Chile
  • Site 40
    Santiago, 7500921, Chile
  • Site 32
    Santiago, 7560908, Chile
  • Site 34
    Santiago, 8330336, Chile
  • Site 25
    Temuco, 76281055-7, Chile
  • Site 205
    Osijek, 31000, Croatia
  • Site 199
    Split, 21000, Croatia
  • Site 204
    Zagreb, 10000, Croatia
  • Site 195
    Olomouc, 779 00, Czechia
  • Site 192
    Prague, 150 06, Czechia
  • Site 56
    Bordeaux, 33075, France
  • Site 101
    Le Mans, 72000, France
  • Site 79
    Lille, 59000, France
  • Site 72
    Lyon, 69378, France
  • Site 57
    Marseille, 13005, France
  • Site 55
    Montpellier, 34298, France
  • Site 66
    Nice, 06189, France
  • Site 105
    Paris, 75005, France
  • Site 143
    Paris, 75013, France
  • Site 87
    Poitiers, 86021, France
  • Site 54
    Rouen, 76038, France
  • Site 59
    Toulouse, 31100, France
  • Site 64
    Vandœuvre-lès-Nancy, 54519, France
  • Site 112
    Villejuif, 94800, France
  • Site 133
    Bonn, 53175, Germany
  • Site 178
    Dortmund, 44137, Germany
  • Site 100
    Dresden, 01307, Germany
  • Site 60
    Greifswald, 17475, Germany
  • Site 82
    Hamburg, 20251, Germany
  • Site 91
    Hamburg, 22763, Germany
  • Site 104
    Hanover, 30625, Germany
  • Site 129
    Mannheim, 68167, Germany
  • Site 148
    München, 81675, Germany
  • Site 121
    Münster, 48149, Germany

Showing the first 100 of 202 sites across 28 countries. Choose a country and city above to see the rest.

08

References and documents

Publications

  • Machiels JP, Fayette J, Haddad R, Adkins D, Gillison M, Harrington KJ, Kim SB, Le Tourneau C, Psyrri A, Rosenberg A, Siu LL, Tahara M, William WN Jr, Ford J, Jauhari S, Pyle R, Shen YM, Yao D, Zohren F, Vokes E. LiGeR-HN phase III trials of petosemtamab + pembrolizumab and petosemtamab monotherapy in recurrent or metastatic HNSCC. Future Oncol. 2025 Jul;21(16):2007-2016. doi: 10.1080/14796694.2025.2511470. Epub 2025 Jun 13. PubMed 40511820 ↗
09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2024 (actual). Primary completion is estimated for Jan 2028, 40 months after the start.

Of 78 phase 3 interventional studies under Squamous Cell Carcinoma of Head and Neck, half reached primary completion within 76 months of starting (the median), counting those still running; a quarter within 38 and three quarters within 117. This study's planned 40 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 24, 2024
First posted
Jul 29, 2024
StartActual
Sep 25, 2024
Primary completionEst.
Jan 2028
CompletionEst.
Jul 2030
Last update
Nov 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Active, not recruiting
changed Sep 25, 2026
Sites
3 sites removed
Show 3 removed
  • Site 48 · Orlando, United States
  • Site 37 · CABA, Argentina
  • Site 47 · Gyeonggi-do, South Korea
Sep 25, 2026
Enrollment
700 (estimated)→699 (actual)
Sep 25, 2026
Sponsor
Merus B.V.→Genmab
Nov 2, 2026
Show all 2 updates
  1. Nov 2, 2026
    Sponsor Merus B.V.→Genmab
    + 4 other changes: identifiers, verification date, site details and contact details
  2. Sep 25, 2026
    Recruiting→Active, not recruiting
    3 sites removed
    Show 3 removed
    • Site 48 · Orlando, United States
    • Site 37 · CABA, Argentina
    • Site 47 · Gyeonggi-do, South Korea
    Enrollment 700 (estimated)→699 (actual)
    + 3 other changes: identifiers, verification date and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06525220
Lead sponsor
Genmab
Responsible party
Sponsor
First posted
Jul 29, 2024
Start date
Sep 25, 2024
Primary completion
Jan 2028 (estimated)
Completion
Jul 2030 (estimated)
Last update
Nov 2, 2026

Study contacts

Study Official
study director · Genmab

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Petosemtamab

Start the discussion